Primary myelofibrosis
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of approximately 1 case per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Primary myelofibrosis
- Therapeutic area
- Hematology
- primary myelofibrosis
- AMM
- Agnogenic myeloid metaplasia
- CIMF
- chronic idiopathic myelofibrosis
- idiopathic bone marrow fibrosis
- idiopathic myelofibrosis
- myelofibrosis with myeloid metaplasia, somatic
- myelofibrosis, somatic
- myelosclerosis with myeloid metaplasia
- osteomyelofibrosis
- primary myelofibrosis
- myelofibrosis with myeloid metaplasia
- myeloid metaplasia
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0009692
- Parent condition
- MONDO:0015610
Related records
Broader conditions (30)
- Acquired aplastic anemia
- Anemia
- Aplastic anemia
- Bone cancer
- Bone disorder
- Bone marrow cancer
- Bone marrow disorder
- Bone marrow neoplasm
- Bone neoplasm
- Cancer
- Cancer or benign tumor
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
Narrower conditions (4)
- Cellular phase chronic idiopathic myelofibrosis
- Familial myelofibrosis
- Myelofibrosis with myeloid metaplasia
- Panostotic fibrous dysplasia
Trials (613)
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.
- 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
- 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
- A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
- A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
- A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
- A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
- A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
- A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept
- A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis
- A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
- A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
Approved drugs (4)
- Fedratinib hydrochloride
- Momelotinib dihydrochloride
- Pacritinib citrate
- Ruxolitinib phosphate
Drugs in development (41)
- ABBV-744 Phase 1
- Arsenic trioxide Phase 1
- Ascorbic acid Phase 1
- AZD-1480 Phase 1
- Busulfan Phase 2
- Captopril Phase 1
- Cyclophosphamide Phase 2
- Durvalumab Phase 1
- Elritercept Phase 1
- Fedratinib Phase 3
- Filgrastim Phase 1
- Fludarabine phosphate Phase 2
- Hydroxyurea Phase 3
- Imatinib mesylate Phase 1
- KB-004 Phase 1
- LCL-161 Phase 2
- Lenalidomide Phase 2
- Melphalan Phase 2
- Methotrexate Phase 2
- Mivebresib Phase 1